股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 維昇藥業 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年12月4日 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02561 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 113,926,864 | | 0 | | 113,926,864 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 113,926,864 | | 0 | | 113,926,864 | 第 2 頁 共 10 頁 v 1.1.1 I. 法定/註冊股本變動 | 1. 股份分類 ...

消息面上，安科生物近期披露合作进展，与维昇药业合作的隆培促生长素即将获批。据悉，7月14日， 安科生物宣布，公司与维昇药业签订战略合作框架协议，共同推动隆培促生长素在中国市场的普及。 智通财经获悉，维昇药业-B(02561)再涨超12%，截至发稿，涨7.11%，报35.26港元，成交额190.82万港 元。 值得注意的是，11月6日，第八届进博会期间，维昇药业与国内制药装备龙头企业东富龙达成双腔冻干 制剂技术战略合作，并与临港新片区管委会、临港集团物贸平台签署产业协同协议，标志着其在"全球 创新、中国加速"的战略实践进一步落地。 本文源自：智通财经网 ...

每经AI快讯，维昇药业-B(02561.HK)涨超12%，截至发稿，涨7.11%，报35.26港元，成交额190.82万港 元。 ...

消息面上，安科生物近期披露合作进展，与维昇药业合作的隆培促生长素即将获批。据悉，7月14日， 安科生物宣布，公司与维昇药业签订战略合作框架协议，共同推动隆培促生长素在中国市场的普及。 值得注意的是，11月6日，第八届进博会期间，维昇药业与国内制药装备龙头企业东富龙达成双腔冻干 制剂技术战略合作，并与临港新片区管委会、临港集团物贸平台签署产业协同协议，标志着其在"全球 创新、中国加速"的战略实践进一步落地。 智通财经APP获悉，维昇药业-B(02561)再涨超12%，截至发稿，涨7.11%，报35.26港元，成交额190.82 万港元。 ...

智通财经获悉，维昇药业-B(02561)盘中涨超7%，截至发稿，涨3.64%，报31.88港元。 消息面上，安科生物近期披露合作进展，与维昇药业合作的隆培促生长素即将获批。据悉，7月14日， 安科生物宣布，公司与维昇药业签订战略合作框架协议，共同推动隆培促生长素在中国市场的普及；维 昇药业的核心产品隆培促生长素于2024年3月获中国国家药监局上市申请受理，预计于2025年下半年获 批上市。 本文源自：智通财经网 ...

（文章来源：每日经济新闻） 每经AI快讯，维昇药业-B(02561.HK)盘中涨超3%，截至发稿，涨3.64%，报31.88港元。 ...

Core Viewpoint - The stock price of Weisheng Pharmaceutical-B (02561) has seen a significant increase, rising over 7% during trading and currently up by 3.64% to HKD 31.88, driven by positive news regarding its collaboration with Anke Bio [1] Group 1: Company Developments - Anke Bio (300009) has recently disclosed progress in its collaboration with Weisheng Pharmaceutical, specifically regarding the approval of Longpei Growth Hormone [1] - On July 14, Anke Bio announced the signing of a strategic cooperation framework agreement with Weisheng Pharmaceutical to promote the Longpei Growth Hormone in the Chinese market [1] - Weisheng Pharmaceutical's core product, Longpei Growth Hormone, had its application for market approval accepted by the National Medical Products Administration of China in March 2024, with expectations for approval in the second half of 2025 [1]

智通财经APP获悉，维昇药业-B(02561)盘中涨超7%，截至发稿，涨3.64%，报31.88港元。 消息面上，安科生物近期披露合作进展，与维昇药业合作的隆培促生长素即将获批。据悉，7月14日， 安科生物宣布，公司与维昇药业签订战略合作框架协议，共同推动隆培促生长素在中国市场的普及；维 昇药业的核心产品隆培促生长素于2024年3月获中国国家药监局上市申请受理，预计于2025年下半年获 批上市。 ...

Summary of Key Points Core Viewpoint - As of November 26, a total of 39 stocks reached their 52-week highs, with notable performances from Fire Rock Holdings (02975), Crocodile Garments (02977), and Aisuo Holdings (08585) showing significant increases in their high rates [1]. 52-Week Highs - Fire Rock Holdings (02975) achieved a closing price of 0.114 with a peak of 0.231, marking a high rate of 285.00% - Crocodile Garments (02977) closed at 0.085, reaching a high of 0.189, reflecting a high rate of 170.00% - Aisuo Holdings (08585) closed at 0.021, with a peak of 0.040, resulting in a high rate of 110.53% - Other notable stocks include: - Fulltech Electric Group Holdings (01750) with a high rate of 23.64% - Century United Holdings (01959) at 22.05% - Cassava Resources (00841) at 20.19% [1]. 52-Week Lows - The stock with the largest decline was Jia Jin Investment International (00310), which closed at 0.141, reaching a low of 0.137, resulting in a decline rate of -25.95% - Crown Central Properties (00193) closed at 0.168, with a low of 0.141, reflecting a decline rate of -18.02% - Lion Holdings (02562) had a closing price of 4.710, with a low of 4.680, showing a decline rate of -9.48% - Other significant declines include: - Huading Holdings (03398) at -7.14% - XL Two South Strategy - U (09799) at -5.96% [2].

Core Viewpoint - The article emphasizes the need to shift the focus in innovative drug investment from "people" to "assets," highlighting the importance of molecules, technologies, and pipelines with significant therapeutic potential and commercial value in the biopharmaceutical sector [5][6]. Group 1: Investment Strategy - Vivo Capital has adopted a new approach called the "accelerator" model, which involves selecting high-quality drug assets globally and establishing new companies (NewCo) to introduce them to China, leveraging China's integrated advantages in clinical trials and resource allocation [6][12]. - The firm has raised $740 million for its public market strategy and currently manages over $7.5 billion in assets, indicating a robust investment capacity [6][8]. - The traditional VC model in biopharmaceuticals is deemed ineffective, as it has led to resource misallocation and excessive reliance on capital markets, which can jeopardize drug development when IPO opportunities diminish [8][9]. Group 2: Market Dynamics - In the first half of 2025, China saw a total upfront payment of approximately $2.64 billion for innovative drug license-out transactions, surpassing the primary market financing total of about $1.62 billion [8]. - The article notes a significant gap between the investment in innovative drugs (approximately $200 billion over the past decade) and the projected annual sales of domestic innovative drugs in 2024 (around 60 billion RMB, or less than $10 billion) [9]. - The article highlights that the investment returns in sectors like food, pharmaceuticals, and aviation are often marginally negative due to their substantial social value, advising investors from non-biopharmaceutical sectors to be cautious [9]. Group 3: Asset Development and Evaluation - The asset development process involves a five-tier evaluation system, including assessments from the original technology company, Vivo Capital, the NewCo board, development partners, and potential buyers [13]. - The decision to advance or halt a project is influenced by both scientific data and dynamic market competition, ensuring efficient resource allocation [13]. - Vivo Capital's investment strategy has evolved through three iterations, culminating in the establishment of the "accelerator" model, which focuses on resource allocation around promising assets [13][19]. Group 4: Leadership and Team Dynamics - The selection of leadership for new ventures is critical, with a focus on finding "drivers" who possess international perspectives and resource integration capabilities rather than traditional founders [18]. - The article emphasizes the need for a collaborative approach among various talent types, including those who identify market needs, researchers, and business development professionals [15][16]. - The challenge lies in accurately assessing individuals' capabilities in a complex and high-barrier industry, where misalignment can lead to resource misallocation [16]. Group 5: Market Outlook - The article expresses optimism about the long-term prospects of the Hong Kong stock market for innovative drugs, despite a recent correction, citing improved asset quality compared to three years ago [20][21]. - Factors contributing to the positive outlook include regulatory alignment with international standards, the return of overseas experts, the rise of specialized service platforms, and substantial capital inflows [21][22]. - The article notes that global pharmaceutical companies currently have approximately $1.2 trillion in available funds, creating opportunities for domestic innovative drug companies to engage in business development transactions [23].